Cerba Research WP
Janssen launches once-daily option for prostate cancer drug Erleada
Erleada is the first and only ARI option avaialable as aa once-daily, single-tablet for nmCRPC and mCSPC.
MHRA fast tracks ADvantage’s immunomodulator for Alzheimer’s disease
Absci and M2GEN partner to expedite cancer drug development
BioNTech and DualityBio team up to develop ADC therapeutics for cancer
HUTCHMED concludes FDA rolling submission for colorectal cancer treatment
Regeneron and Sonoma Biotherapeutics partner to develop T cell therapies
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
